lanreotide autogel + octreotide LAR

Lanreotide Autogel + Octreotide LAR refers to a clinical trial context comparing two long-acting somatostatin analogues used in the treatment of acromegaly. Lanreotide Autogel (marketed as Somatuline Depot/Autogel by Ipsen) is a prolonged-release aqueous formulation, while Octreotide LAR (marketed as Sandostatin LAR by Novartis) is a long-acting release formulation. Both drugs function as agonists of somatostatin receptors, particularly SSTR2 and SSTR5, to suppress the hypersecretion of growth hormone (GH) and normalize insulin-like growth factor-I (IGF-I) levels. The specific study conducted by Odense University Hospital was a twelve-month randomized crossover trial (NCT00692315) designed to evaluate the comparative efficacy, biochemical control, and patient satisfaction between these two therapeutic modalities in patients with acromegaly.

Brand names

Somatuline AutogelSandostatin LARSomatuline Depot

Other names

Lanreotide AutogelOctreotide LARLanreotide DepotOctreotide Long-Acting Release